- Home
- AMBP vs IDYA Comparison
AMBP vs IDYA Comparison
Compare AMBP & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBP
- IDYA
- Stock Information
- Founded
- AMBP 2021
- IDYA 2015
- Country
- AMBP Luxembourg
- IDYA United States
- Employees
- AMBP N/A
- IDYA N/A
- Industry
- AMBP Containers/Packaging
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- AMBP Industrials
- IDYA Health Care
- Exchange
- AMBP Nasdaq
- IDYA Nasdaq
- Market Cap
- AMBP 2.2B
- IDYA 2.6B
- IPO Year
- AMBP N/A
- IDYA 2019
- Fundamental
- Price
- AMBP $3.67
- IDYA $25.90
- Analyst Decision
- AMBP Hold
- IDYA Strong Buy
- Analyst Count
- AMBP 7
- IDYA 12
- Target Price
- AMBP $3.85
- IDYA $53.67
- AVG Volume (30 Days)
- AMBP 1.7M
- IDYA 769.7K
- Earning Date
- AMBP 10-24-2024
- IDYA 11-04-2024
- Dividend Yield
- AMBP 11.10%
- IDYA N/A
- EPS Growth
- AMBP N/A
- IDYA N/A
- EPS
- AMBP N/A
- IDYA N/A
- Revenue
- AMBP $4,845,000,000.00
- IDYA $3,922,000.00
- Revenue This Year
- AMBP $3.26
- IDYA N/A
- Revenue Next Year
- AMBP $3.74
- IDYA $158.10
- P/E Ratio
- AMBP N/A
- IDYA N/A
- Revenue Growth
- AMBP 1.87
- IDYA N/A
- 52 Week Low
- AMBP $3.16
- IDYA $25.37
- 52 Week High
- AMBP $4.26
- IDYA $47.74
- Technical
- Relative Strength Index (RSI)
- AMBP 39.55
- IDYA 31.14
- Support Level
- AMBP $3.65
- IDYA $25.35
- Resistance Level
- AMBP $3.65
- IDYA $32.67
- Average True Range (ATR)
- AMBP 0.09
- IDYA 1.41
- MACD
- AMBP -0.01
- IDYA -0.43
- Stochastic Oscillator
- AMBP 7.69
- IDYA 3.28
About AMBP Ardagh Metal Packaging S.A.
Ardagh Metal Packaging SA is a supplier of infinitely recyclable, sustainable, metal beverage cans and ends to brand owners. Its segment includes Europe and the Americas. It derives a majority of its revenue from the Americas.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.